Iranian Journal of Pathology

Comparison of 5FU-base Chemoradiation with and without Eloxatin on Pathologic Complete Response in Neoadjuvant Chemoradiation of Rectal cancer

Document Type : Original Research

Authors

Ali Yaghoubi 1
Payam Azadeh 1
KhosroM M Sheibani 1
Mohammad Foudazi 2
Behrouz Shafaghi 3
Manouchehr Davaei 3

1 Dept. of Radiation Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2 Dept. of Surgery, Shahid Beheshti University of Medical Sciences, Tehran, Iran

3 Dept. of Pathology, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract
 
Background and Objectives: To compare pathologic complete response (pCR) in patients with advanced rectal cancer receiving neoadjuvant chemoradiotherapy (NACT) by 5-FU or Xeloda (capecitabine) with and without Eloxatin (oxaloplatin injection).
Materials and Methods: Seventy-five consecutive patients with the diagnosis of advanced rectal adenocarcinoma were included. Two basic chemotherapy regimens were used: one drug (5-FU or Xeloda) or two-drug (5-U or Xeloda with Eloxatin). Endpoints were pCR and preservation of sphincter during surgery through low anterior resection (LAR). All analyses were done using SPSS software version 17.0 (SPSS Inc., Chicago, IL).
Results: There were no significant differences between the group of patients who received one-drug regimen with those who received two-drug regimen regarding the pCR (four cases (23.5%) versus 25 vases (43.1%)) state or the type of surgery performed [nine cases (52.9%) versus 36 cases (62.1%)].
Conclusion: Adding Eloxatin to the standard treatment of rectal adenocarcinoma (5-FU based) did not yield in a higher pCR or a higher chance to preserve the anal sphincter.
 

Keywords

Eloxatin
5FU
Rectum
Adenocarcinoma
Iranian Journal of Pathology
Volume 6, Issue 3 - Serial Number 3
Summer 2011
Pages 110-116

  • Receive Date 19 September 2014

Home

Guide for Authors

Submit Manuscript

Contact Us